评估注意缺陷多动障碍药物试验的代表性:一项比较假设符合试验条件与不符合试验条件的个体的瑞典人群研究
该研究利用瑞典多个国家登记数据,纳入2007年1月1日至2019年12月31日期间开始药物治疗的189 699名注意缺陷多动障碍(ADHD)患者,基于164项随机对照试验(RCT)的排除标准判定假设不合格比例。53%的患者假设不符合RCT条件,不合格者治疗切换风险更高(HR 1.14),精神科住院(IRR 9.68)及物质使用障碍、抑郁、焦虑相关专科就诊率更高。
要点
- 53%的ADHD药物治疗患者假设不符合RCT条件,成人中比例达74%。
- 不符合RCT条件者治疗切换风险更高(HR 1.14),停药可能性更低(HR 0.96)。
- 不符合RCT条件者精神科住院(IRR 9.68)及物质使用障碍、抑郁、焦虑相关就诊率更高。
核心结论
- 不符合ADHD药物试验条件的个体面临更高的不良结局风险。
- 该研究首次提供实证证据表明ADHD随机对照试验对真实临床人群的推广性有限。
- 整合随机对照试验与真实世界研究的证据对于制定严谨的循证治疗指南至关重要。
研究设计与样本
- 利用瑞典多个国家登记数据识别诊断为ADHD且年龄至少4岁、于2007年1月1日至2019年12月31日期间开始药物治疗的个体,随访至2020年12月31日。
- 假设性RCT不合格依据来自国际MED-ADHD数据集(包含164项ADHD药物RCT)的排除标准。
- 采用Cox模型评估合格与不合格个体在1年内药物切换和停药差异,采用准泊松模型比较1年内精神科住院、伤害或事故及物质使用障碍发生率。
- 有ADHD亲身经历者未参与研究和写作过程。
主要发现
- 研究队列共纳入189 699名开始ADHD药物治疗的个体(112 153名男性及男孩[59%],77 546名女性及女孩[41%];平均年龄21.52岁[SD 12.83;范围4-68])。
- 53%的个体假设不符合RCT参与条件(成人[>17岁]76 477/103 023[74%],青少年[13-17岁]12 658/35 681[35%],儿童[<13岁]10 643/50 995[21%])。
- 不合格个体治疗切换可能性更高(HR 1.14,95% CI 1.12-1.16),停药可能性更低(HR 0.96,95% CI 0.94-0.98)。
- 不合格个体精神科住院率(IRR 9.68,95% CI 9.57-9.78)及物质使用障碍(IRR 14.78,95% CI 14.64-14.91)、抑郁(IRR 6.00,95% CI 5.94-6.06)、焦虑(IRR 11.63,95% CI 11.56-11.69)相关专科就诊率显著更高。
关键数值与推荐
- 假设性RCT不合格判定采用国际MED-ADHD数据集(含164项ADHD药物RCT)的排除标准。
- 不符合RCT条件者治疗切换HR 1.14(95% CI 1.12-1.16),停药HR 0.96(95% CI 0.94-0.98)。
- 不符合RCT条件者精神科住院IRR 9.68(95% CI 9.57-9.78),物质使用障碍相关专科就诊IRR 14.78(95% CI 14.64-14.91),抑郁相关IRR 6.00(95% CI 5.94-6.06),焦虑相关IRR 11.63(95% CI 11.56-11.69)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
- 种族数据不可用。
- 有ADHD亲身经历者未参与研究和写作过程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomised controlled trials (RCTs) evaluating ADHD medications often use strict eligibility criteria, potentially limiting generalisability to patients in real-world clinical settings. We aimed to identify the proportion of individuals with ADHD who would be ineligible for medication RCTs and evaluate differences in treatment patterns and clinical and functional outcomes between RCT-eligible and RCT-ineligible individuals. METHODS: We used multiple Swedish national registries to identify individuals with ADHD, aged at least 4 years at the age of diagnosis, initiating pharmacological treatment between Jan 1, 2007, and Dec 31, 2019, with follow-up up to Dec 31, 2020. Hypothetical RCT ineligibility was established using exclusion criteria from the international MED-ADHD dataset, including 164 RCTs of ADHD medications. Cox models evaluated differences in medication switching and discontinuation within 1 year between eligible and ineligible individuals. Quasi-Poisson models compared eligible and ineligible individuals on rates of psychiatric hospitalisations, injuries or accidents, and substance use disorder within 1 year of initiating ADHD medications. People with lived experience of ADHD were not involved in the research and writing process. FINDINGS: Of 189 699 individuals included in the study cohort (112 153 men and boys [59%] and 77 546 women and girls [41%]; mean age 21·52 years [SD 12·83; range 4-68]) initiating ADHD medication, 53% (76 477 [74%] of 103 023 adults [aged >17 years], 12 658 [35%] of 35 681 adolescents [aged 13-17 years], and 10 643 [21%] of 50 995 children [aged <13 years]) would have been ineligible for RCT participation. Ethnicity data were not available. Ineligible individuals had a higher likelihood of treatment switching (hazard ratio 1·14, 95% CI 1·12-1·16) and a decreased likelihood of medication discontinuation (0·96, 0·94-0·98) compared with eligible individuals. Individuals ineligible for RCTs had significantly higher rates of psychiatric hospitalisations (ncidence rate ratio 9·68, 95% CI 9·57-9·78) and specialist care visits related to substance use disorder (14·78, 14·64-14·91), depression (6·00, 5·94-6·06), and anxiety (11·63, 11·56-11·69). INTERPRETATION: Individuals ineligible for ADHD medication trials face higher risks of adverse outcomes. This study provides the first empirical evidence for the limited generalisability of ADHD RCTs to real-world clinical populations, by applying eligibility criteria extracted from a comprehensive dataset of RCTs to a large real-world cohort. Triangulating evidence from RCTs and real-world studies is crucial to inform rigorous evidence-based treatment guidelines. FUNDING: National Institute of Healthcare and Research, European Union's Horizon 2020, and Swedish Research Council.
引用
- Garcia-Argibay M, Chang Z, Brikell I, et al. Evaluating ADHD medication trial representativeness: a Swedish population-based study comparing hypothetically trial-eligible and trial-ineligible individuals. Lancet Psychiatry. 2025. PMID: 39788146. doi:10.1016/S2215-0366(24)00396-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。